Comparative Pharmacology
Head-to-head clinical analysis: GRISACTIN versus NOXAFIL POWDERMIX KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRISACTIN versus NOXAFIL POWDERMIX KIT.
GRISACTIN vs NOXAFIL POWDERMIX KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to microtubules and disrupts mitotic spindle formation, inhibiting fungal cell division.
Posaconazole inhibits fungal CYP450-dependent 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
500 mg orally once daily or 250 mg orally twice daily for dermatophyte infections.
300 mg (one 300-mg vial) intravenously twice on day 1, then 300 mg intravenously once daily starting on day 2. Alternatively, oral suspension: 200 mg (10 mL) three times daily. For prophylaxis, IV: 300 mg twice on day 1, then 300 mg once daily; oral: 200 mg three times daily.
None Documented
None Documented
Terminal elimination half-life: 9–24 hours (mean ~14 hours). Clinical context: Steady-state achieved in 3–5 days; once-daily dosing is effective due to prolonged half-life.
The terminal elimination half-life is approximately 27 hours (range 20-66 hours) in healthy subjects, allowing for once-daily dosing after steady state.
Renal: <1% as intact drug; fecal: >99% as metabolites (mainly 6-demethylgriseofulvin glucuronide) via bile; negligible biliary excretion of parent compound.
Posaconazole is primarily excreted in the feces (77%) as unchanged drug, with renal excretion accounting for 14% of the dose (primarily as glucuronide conjugates). Less than 0.2% is excreted unchanged in urine.
Category C
Category C
Antifungal
Antifungal